Inovio Pharma (NASDAQ: INO) reported Q1 EPS of $0.16, $0.31 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $110 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.